Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users
- PMID: 32327162
- DOI: 10.1016/j.jval.2019.12.002
Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users
Abstract
Objectives: To determine the cost-effectiveness of pharmacy-based intranasal naloxone distribution to high-risk prescription opioid (RxO) users.
Methods: We developed a Markov model with an attached tree for pharmacy-based naloxone distribution to high-risk RxO users using 2 approaches: one-time and biannual follow-up distribution. The Markov structure had 6 health states: high-risk RxO use, low-risk RxO use, no RxO use, illicit opioid use, no illicit opioid use, and death. The tree modeled the probability of an overdose happening, the overdose being witnessed, naloxone being available, and the overdose resulting in death. High-risk RxO users were defined as individuals with prescription opioid doses greater than or equal to 90 morphine milligram equivalents (MME) per day. We used a monthly cycle length, lifetime horizon, and US healthcare perspective. Costs (2018) and quality-adjusted life-years (QALYs) were discounted 3% annually. Microsimulation was performed with 100 000 individual trials. Deterministic and probabilistic sensitivity analyses were conducted.
Results: One-time distribution of naloxone prevented 14 additional overdose deaths per 100 000 persons, with an incremental cost-effectiveness ratio (ICER) of $56 699 per QALY. Biannual follow-up distribution led to 107 additional lives being saved with an ICER of $84 799 per QALY compared with one-time distribution. Probabilistic sensitivity analyses showed that a biannual follow-up approach would be cost-effective 50% of the time at a willingness-to-pay (WTP) threshold of $100 000 per QALY. Naloxone effectiveness and proportion of overdoses witnessed were the 2 most influential parameters for biannual distribution.
Conclusion: Both one-time and biannual follow-up naloxone distribution in community pharmacies would modestly reduce opioid overdose deaths and be cost-effective at a WTP of $100 000 per QALY.
Keywords: cost-effectiveness; naloxone; overdose; pharmacists.
Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom.Value Health. 2018 Apr;21(4):407-415. doi: 10.1016/j.jval.2017.07.014. Epub 2018 Feb 4. Value Health. 2018. PMID: 29680097
-
Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities.J Med Econ. 2013 Aug;16(8):1051-60. doi: 10.3111/13696998.2013.811080. Epub 2013 Jun 19. J Med Econ. 2013. PMID: 23730942
-
Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal.Ann Intern Med. 2013 Jan 1;158(1):1-9. doi: 10.7326/0003-4819-158-1-201301010-00003. Ann Intern Med. 2013. PMID: 23277895
-
What is known about community pharmacy supply of naloxone? A scoping review.Int J Drug Policy. 2016 Jun;32:24-33. doi: 10.1016/j.drugpo.2016.02.006. Epub 2016 Feb 15. Int J Drug Policy. 2016. PMID: 26949189 Review.
-
Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know.Addict Sci Clin Pract. 2017 Jan 7;12(1):4. doi: 10.1186/s13722-016-0068-3. Addict Sci Clin Pract. 2017. PMID: 28061909 Free PMC article. Review.
Cited by
-
Bystanders Saving Lives with Naloxone: A Scoping Review on Methods to Estimate Overdose Reversals.West J Emerg Med. 2024 Jul;25(4):500-506. doi: 10.5811/westjem.18037. West J Emerg Med. 2024. PMID: 39028236 Free PMC article. Review.
-
An economic evaluation of community pharmacy-dispensed naloxone in Canada.Can Pharm J (Ott). 2024 Feb 13;157(2):84-94. doi: 10.1177/17151635241228241. eCollection 2024 Mar-Apr. Can Pharm J (Ott). 2024. PMID: 38463179 Free PMC article.
-
Updated Estimates of Annual U.S. Health System Spending from a Hypothetical National Naloxone Co-Prescribing Mandate.Subst Use Misuse. 2023;58(13):1707-1713. doi: 10.1080/10826084.2023.2244065. Epub 2023 Aug 23. Subst Use Misuse. 2023. PMID: 37614062
-
Organizational Readiness to Implement Community Pharmacy-Based Opioid Counseling and Naloxone Services: A Scoping Review of Current Practice Models and Opportunities.Pharmacy (Basel). 2023 Jun 11;11(3):99. doi: 10.3390/pharmacy11030099. Pharmacy (Basel). 2023. PMID: 37368424 Free PMC article. Review.
-
Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island.JAMA Netw Open. 2022 Nov 1;5(11):e2241174. doi: 10.1001/jamanetworkopen.2022.41174. JAMA Netw Open. 2022. PMID: 36350649 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous